Li Xu
About Li Xu
Li Xu serves as the Senior Director of Quality Control at Inozyme Pharma, bringing extensive experience in analytical development and quality control from previous roles at Ra Pharmaceuticals, PepGen, and UCB.
Current Role at Inozyme
Li Xu serves as the Senior Director of Quality Control (QC) at Inozyme Pharma. He has held this position since 2023, contributing to the company's focus on developing innovative therapies. His role involves overseeing quality control processes and ensuring compliance with industry standards in Boston, Massachusetts.
Previous Experience at Ra Pharmaceuticals
Li Xu worked at Ra Pharmaceuticals in two capacities. He first served as Associate Director of Analytical Development/QC from 2017 to 2019, where he focused on analytical methods and quality assurance. He then advanced to the role of Director of Analytical Development/QC from 2019 to 2020, further enhancing the company's analytical capabilities in Cambridge, Massachusetts.
Experience at PepGen
At PepGen, Li Xu held the position of Director of Analytical Development and QC from 2021 to 2023. During his tenure, he was responsible for leading analytical development initiatives and quality control efforts, contributing to the company's research and development objectives in Cambridge, Massachusetts.
Career at AMRI
Li Xu began his career at Albany Molecular Research Inc. (AMRI), where he worked as a Senior Research Scientist I-III from 2008 to 2017. His nine years at AMRI involved significant contributions to research and development, focusing on analytical techniques and methodologies in the Albany, New York Area.
Educational Background
Li Xu earned a Ph.D. in Environmental Health Science from the University at Albany, SUNY. His academic background provides a strong foundation for his work in analytical development and quality control within the pharmaceutical industry.